🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Abbott Labs is sued over PediaSure height claims

Published 05/15/2023, 02:39 PM
Updated 05/15/2023, 05:41 PM
© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone.  REUTERS/Eric Cox
ABT
-

By Jonathan Stempel

NEW YORK (Reuters) -A New York City woman sued Abbott Laboratories (NYSE:ABT) on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height.

In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller.

The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.

Noriega dismissed PediaSure as "just a flavored sugar and milk-based drink that contains vitamins, which is not a cure for shortness." She said also that Abbott "knows from its own studies that its Clinically Proven Claim is false and misleading."

The lawsuit seeks unspecified damages for New Yorkers who were allegedly deceived into buying or overpaying for PediaSure.

"This case is without merit," Abbott said in a statement. "PediaSure is a scientifically designed complete and balanced nutrition solution for children to help support growth and development."

Lawyers for Noriega did not respond to requests for comment, including additional information about her grandson.

Abbott says PediaSure is intended for children ages two to 13, and has been clinically shown to help children "grow out of at-risk weight-for-height percentiles (5th-25th percentiles)" within eight weeks.

PediaSure is part of the Abbott Park, Illinois-based company's pediatric nutritional segment, which also includes Pedialyte and Similac.

U.S. sales from that unit fell 29% last year, in large part because of Abbott's recall of infant formula from a Michigan plant.

The case is Noriega v Abbott Laboratories, U.S. District Court, Southern District of New York, No. 23-04014.

© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone.  REUTERS/Eric Cox

For plaintiff: James Denlea, of Denlea & Carton; and Philip Smith, of Kravit Smith

For Abbott: Not known

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.